Researchers at the University of Florida have developed a new experimental mRNA vaccine that could open the door to a universal cancer treatment. Unlike most cancer vaccines, which are built to target specific tumour markers, this one works more broadly. It stimulates the immune system and makes tumours more receptive to immunotherapy. As outlined in UF Health’s announcement, when mice were treated with the vaccine alongside immune checkpoint inhibitors, tumours from melanoma, bone, brain and skin cancers either shrank significantly or disappeared entirely. Even more striking, a single dose successfully eliminated infections from antibiotic-resistant Acinetobacter baumannii, and showed no signs of toxicity.
The findings, published in Nature Biomedical Engineering, highlight how the vaccine doesn’t rely on targeting a specific tumour protein. Instead, it mimics a viral infection to trigger PD-L1 expression in tumour cells, which flags them for destruction by the immune system’s T cells. Oncologist Dr. Elias Sayour, who led the study, noted the surprising outcome that even a non-specific mRNA vaccine “could lead to tumour-specific effects.” In the mouse trials, combining the vaccine with immunotherapy led to consistently strong anti-tumour responses, and in some cases, the vaccine alone was enough to eliminate the cancer.
What makes this approach different, and why it matters
Most cancer vaccines under development focus on identifying and responding to unique tumour signatures. But this new strategy flips the concept: instead of personalisation, it primes the immune system in a generalised way that allows existing therapies like checkpoint inhibitors to work more effectively. Co-author Dr. Duane Mitchell described it as aiming for a “strong immunological reaction,” with the goal of producing an off-the-shelf vaccine that could be used across a wide range of cancer types.
That broad immune activation is made possible by tweaking PD-L1 levels, making tumour cells more visible to the immune system. According to UF Health, this alone dramatically boosted the performance of immunotherapies in lab models. While the idea of using mRNA platforms isn’t new, applying them in this way, by focusing on the immune environment rather than the tumour itself, marks a meaningful change.
In recent tests, resistant tumours that didn’t respond to other treatments were either significantly reduced or eradicated. This comes off the back of promising results in trials involving glioblastoma, an aggressive brain cancer where an earlier version of the jab showed a strong immune response. The researchers are now preparing for human trials to test safety and effectiveness in people, building on lessons from COVID-19 vaccine development that used similar lipid nanoparticle delivery systems.
Where the UK fits into the bigger picture
The UK is already investing heavily in mRNA cancer vaccines through initiatives like the NHS’s Cancer Vaccine Launch Pad, which supports personalised mRNA cancer jab trials across a range of tumour types. These projects are being developed in partnership with companies like Moderna, whose mRNA-4157 vaccine has already shown it can reduce melanoma recurrence rates by 44% in early trials. Oxford’s Dr. Lennard Lee has described these vaccines as one of the major medical advances sparked by pandemic-era breakthroughs.
The real game changer here is scale. Personalised vaccines take time, money, and sophisticated tumour mapping. A universal mRNA cancer vaccine, like the one in development at UF, could sidestep those issues entirely. If proven safe and effective, it could be mass-produced and delivered to patients quickly, providing a critical new option in cancer care. That would be especially impactful when paired with immunotherapy drugs, allowing for earlier intervention or use in hard-to-treat cancers.
Of course, it’s early days. Mouse studies are promising, but translating those results to human systems is notoriously difficult. There are also political and regulatory hurdles. As reported by The Guardian, mRNA research in the US has come under pressure from shifting political priorities and funding uncertainty. Despite that, the research community remains hopeful. As covered in The Economic Times, there’s cautious optimism that this approach could lead to a much-needed breakthrough.
If successful, this kind of vaccine could open the door to a fast, effective, and accessible way to treat a wide range of cancers, without needing to customise the jab for each patient. It’s not just another incremental advance. It could completely reshape how we fight cancer.